Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00278200 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00278200 is a Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 23 participants.
The verdict
NCT00278200, a Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's white blood cells may help the body build an effective immune response. PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating patients who are being considered for solid organ transplant who are at risk for post-transplant lymphoproliferative disorder.
Interventions
- BIOLOGICAL Inactivated EBV-infected vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2003-01 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00278200
The ClinicalTrials.gov registry entry for NCT00278200 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inactivated EBV-infected vaccine is the first listed.
NCT00278200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00278200 about?
NCT00278200 is a clinical study titled "Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD". RATIONALE: Vaccines made from a person's white blood cells may help the body build an effective immune response. PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating patients who are being considered for solid organ transplant who are at risk for post-transplant l...
What is the current status of trial NCT00278200?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2003-01. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00278200?
The interventions under investigation include: Inactivated EBV-infected vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00278200?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.